Literature DB >> 16351761

High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart.

Cara L Frankenfeld1, Charlotte Atkinson, Wendy K Thomas, Alex Gonzalez, Tuija Jokela, Kristiina Wähälä, Stephen M Schwartz, Shuying S Li, Johanna W Lampe.   

Abstract

Particular intestinal bacteria are capable of metabolizing the soya isoflavone daidzein to equol and/or O-desmethylangolensin (O-DMA), and the presence of these metabolites in urine after soya consumption are markers of particular intestinal bacteria profiles. Prevalences of equol producers and O-DMA producers are approximately 30-50 % and 80-90 %, respectively, and limited observations have suggested that these daidzein-metabolizing phenotypes are stable within individuals over time. Characterizing stability of these phenotypes is important to understand their potential as markers of long-term exposure to particular intestinal bacteria and their associations with disease risk. We evaluated concordance within an individual for the equol-producer and O-DMA-producer phenotypes measured at two time points (T1, T2), 1-3 years apart. Phenotypes were ascertained by analysing equol and O-DMA using GC-MS in a spot urine sample collected after 3 d soya (source of daidzein) supplementation. In ninety-two individuals without recent (within 3 months before phenotyping) or current antibiotics use, 41 % were equol producers at T1 and 45 % were equol producers at T2, and 90 % were O-DMA producers at T1 and 95 % were O-DMA producers at T2. The percentage agreement for the equol-producer phenotype was 82 and for the O-DMA-producer phenotype was 89. These results indicate that these phenotypes are stable in most individuals over time, suggesting that they provide a useful biomarker for evaluating disease risk associated with harbouring particular intestinal bacteria responsible for, or associated with, the metabolism of the soya isoflavone daidzein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351761     DOI: 10.1079/bjn20051565

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  26 in total

1.  Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.

Authors:  Jennifer H Ahn-Jarvis; Steven K Clinton; Elizabeth M Grainger; Kenneth M Riedl; Steven J Schwartz; Mei-Ling T Lee; Raul Cruz-Cano; Gregory S Young; Gregory B Lesinski; Yael Vodovotz
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

2.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites.

Authors:  William R Wikoff; Andrew T Anfora; Jun Liu; Peter G Schultz; Scott A Lesley; Eric C Peters; Gary Siuzdak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

3.  Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein.

Authors:  C L Frankenfeld; C Atkinson; K Wähälä; J W Lampe
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 4.  Phytoestrogenic isoflavonoids in epidemiologic and clinical research.

Authors:  Adrian A Franke; Brunhild M Halm; Kerry Kakazu; Xingnan Li; Laurie J Custer
Journal:  Drug Test Anal       Date:  2009-01       Impact factor: 3.345

5.  Equol production changes over time in pre-menopausal women.

Authors:  Adrian A Franke; Jennifer F Lai; Ian Pagano; Yukiko Morimoto; Gertraud Maskarinec
Journal:  Br J Nutr       Date:  2011-09-16       Impact factor: 3.718

Review 6.  Therapeutic perspectives of epigenetically active nutrients.

Authors:  M Remely; L Lovrecic; A L de la Garza; L Migliore; B Peterlin; F I Milagro; A J Martinez; A G Haslberger
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

7.  S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Authors:  Mandeep K Virk-Baker; Stephen Barnes; Helen Krontiras; Tim R Nagy
Journal:  Nutr Res       Date:  2013-12-18       Impact factor: 3.315

8.  Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Charlotte Atkinson; Roberta M Ray; Wenjin Li; Ming-Gang Lin; Dao Li Gao; Jackilen Shannon; Helge Stalsberg; Peggy L Porter; Cara L Frankenfeld; Kristiina Wähälä; David B Thomas; Johanna W Lampe
Journal:  Nutr Res       Date:  2016-03-30       Impact factor: 3.315

9.  Is equol the key to the efficacy of soy foods?

Authors:  Johanna W Lampe
Journal:  Am J Clin Nutr       Date:  2009-04-08       Impact factor: 7.045

10.  Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures.

Authors:  Takuya Ohtomo; Mariko Uehara; José Luis Peñalvo; Herman Adlercreutz; Shin-ichi Katsumata; Kazuharu Suzuki; Ken Takeda; Ritsuko Masuyama; Yoshiko Ishimi
Journal:  Eur J Nutr       Date:  2008-07-11       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.